Martin Coker
Family Medicine · Richland, WANPI 1225082811
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 347 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,218 and has fallen 98.4% since, to $35 in 2024. Among family medicine clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 347 payments — averaging $16.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$835
- Amgen$476
- Boehringer Ingelheim$394
- AbbVie$370
- GSK$358
- plus $2K from 33 others
What the payments were for
- Food & beverage$5,66698%
- Education$982%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 62 | $1,246 |
| Novo Nordisk | 54 | $835 |
| Amgen | 28 | $476 |
| Boehringer Ingelheim | 24 | $394 |
| AbbVie(2 entities) | 23 | $370 |
| GSK | 21 | $358 |
| Teva Pharmaceuticals USA, Inc. | 24 | $313 |
| Amarin Pharma, Inc. | 13 | $217 |
| Johnson & Johnson | 14 | $210 |
| Pfizer | 10 | $165 |
| Novartis | 8 | $139 |
| Lilly USA, LLC | 7 | $113 |
| Biohaven Pharmaceuticals, Inc. | 4 | $70 |
| Merck | 5 | $64 |
| Kowa Pharmaceuticals America, Inc. | 4 | $60 |
| Eisai Inc. | 4 | $59 |
| Mylan Specialty L.p. | 3 | $56 |
| Esperion Therapeutics, Inc. | 3 | $52 |
| E.r. Squibb & Sons, L.L.C. | 3 | $48 |
| AMAG Pharmaceuticals, Inc. | 3 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Shire North American Group Inc | 3 | $46 |
| Grifols USA, LLC | 3 | $43 |
| Supernus Pharmaceuticals, Inc. | 2 | $37 |
| Abiomed | 1 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Bayer | 2 | $29 |
| Hologic Sales And Service, LLC | 2 | $29 |
| Radius Health, Inc. | 2 | $28 |
| Kaleo, Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $17 |
| Therapeuticsmd, Inc. | 1 | $16 |
| Abbott | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Circassia Inc. | 1 | $14 |
| Gilead | 1 | $13 |
| Alfasigma USA, Inc. | 1 | $12 |
| Upsher-smith Laboratories LLC | 1 | $12 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$333
- SYMBICORT$213
- Xultophy 100/3.6$117
- BREZTRI AEROSPHERE$108
- FASENRA$105
How this compares
$5,765 in reported general payments places this provider in the 95th percentile of 2,275 family medicine providers in Washington.
Other family medicine in Richland
- Douglas CrawfordRichland$11K
- Kevin HatfieldSeattle$527K
- Marta KazymyraBlaine$222K
- Donella YoungDavenport$175K
- Robert McIntyreSeattle$107K
- James MorenBellingham$106K
- Marshall BrownPasco$70K
- Cynthia CoteMaple Valley$66K
- Greg LedgerwoodBrewster$66K
- Daniel RivasBurien$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.